DexCom Inc
Change company Symbol lookup
Select an option...
DXCM DexCom Inc
LOW Lowe's Companies Inc
BAC Bank of America Corp
ECF Ellsworth Growth and Income Fund Ltd
EBF Ennis Inc
EARN Ellington Residential Mortgage REIT
DXC DXC Technology Co
DX Dynex Capital Inc
DVYE iShares Emerging Markets Dividend ETF
DUK Duke Energy Corp
Go

Health Care : Health Care Equipment & Supplies | Large Cap Growth
Company profile

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

Closing Price
$312.55
Day's Change
-0.77 (-0.25%)
Bid
--
Ask
--
B/A Size
--
Day's High
320.14
Day's Low
311.01
Volume
(Below Average)
Volume:
817,837

10-day average volume:
990,977
817,837

DXCM's position in the Health Care Equipment & Supplies industry

Industry PeersDXCMABTPODDTNDM

Summary

Company ProfileDexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people...
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established...
Go to ABT summary
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent...
Go to PODD summary
Tandem Diabetes Care, Inc. is a medical device company engaged in the designing, developing and commercialization of products for people with insulin-dependent diabetes. The Company’s manufacturing...
Go to TNDM summary
52-Week Change

VS. INDUSTRY
37.81%
25.94%
37.37%
28.11%
Market Cap

VS. INDUSTRY
$30.8B
$193.7B
$17.5B
$5.8B
Beta

VS. INDUSTRY
0.9
0.9
0.8
0.3
Dividend Yield

VS. INDUSTRY
--
1.32%
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
132.93x
58.13x
607.96x
--
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$1.8B
$32.2B
$867.7M
$439.2M
Profit Margin

VS. INDUSTRY
12.69%
10.41%
3.33%
-11.10%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
--
12.40%
--
--
Revenue Growth (TTM)

VS. INDUSTRY
34.74%
2.76%
25.08%
33.04%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.